Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Merck & Co Inc (MRK) stock saw a decline, ending the day at $95.55 which represents a decrease of $-1.08 or -1.12% from the prior close of $96.63. The stock opened at $96.79 and touched a low of ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

The U.S. consumer prices report released this week revealed ... We believe investors with a long-term horizon should hold MRK stock, while short-term investors should consider selling it.

Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Merck & Co., Inc. in a note issued to ...

On Friday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $99.25 which represents a decrease of $-0.60 or -0.60% from the prior close of $99.85. The stock opened at $99.21 and touched a ...

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

BMO Capital analyst Evan Seigerman has maintained their neutral stance on MRK stock, giving a Hold rating on January 10.Stay Ahead of the ...